GlaxoSmithKline and Theravance have announced positive results from two Phase III studies, which showed that patients with Chronic Obstructive Pulmonary...
GlaxoSmithKline and Innoviva announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta...
The FDA has approved Breo Ellipta (fluticasone furoate/vilanterol [FF/VI]), from Glaxo Smith Kline, for the once-daily treatment of asthma in...
GlaxoSmithKline has announced that the European Commission has granted marketing authorisation for Incruse (umeclidinium) powder delivered by the Ellipta inhaler,...
GlaxoSmithKline plc and Theravance, Inc. have announced that the FDA has on 18 December 2013, approved Anoro Ellipta a combination...
GlaxoSmithKline plc announced that the FDA has on 20 August 2014 approved Arnuity Ellipta (fluticasone furoate inhalation powder), a once-daily...
GlaxoSmithKline has announced that the FDA has approved Incruse Ellipta (umeclidinium) as an anticholinergic indicated for the long-term, once-daily, maintenance...
GlaxoSmithKline plc and Theravance, Inc. announced the submission of a supplemental New Drug Application (sNDA) to the FDA for a...
GlaxoSmithKline plc and Theravance, Inc. announced that the European Commission has on 18 November 2013, granted marketing authorisation for Relvar...
CHMP recommends change to authorisation for Relvar Ellipta in asthma.